Author

Tongfu Jia

Observed name: Tong-Fu Jia

Observed institution: Central Hospital of Zibo

OpenAlex ID: A5017484387

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study

2023 · Jin Li, Shukui Qin, et al. · BMC Medicine · 37

PDF

miRNA-148b regulates radioresistance in non-small lung cancer cells via regulation of MutL homologue 1

2016 · Guangsheng Zhai, Gaozhong Li, et al. · Bioscience Reports · 15

Expression of IER3 in Primary Hepatocarcinoma: Correlation with Clinicopathological Parameters

2015 · Zhong Liu, Xin-Mei Wang, et al. · Asian Pacific Journal of Cancer Prevention · 8

PDF

Initial dose of apatinib in Chinese patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting: 500 mg or 850 mg?

2018 · Wenying Deng, Shukui Qin, et al. · Journal of Clinical Oncology · 5

Safety of apatinib as third-line or beyond treatment in advanced or metastatic gastric cancer: Results from a multicenter phase IV study (Ahead-G201).

2018 · Jin Li, Lu Wen, et al. · Journal of Clinical Oncology · 2

Safety and efficacy of apatinib as third or later line treatment for advanced gastric cancer or gastroesophageal junction adenocarcinoma: A post-marketing phase IV study.

2021 · Jin Li, Shukui Qin, et al. · Journal of Clinical Oncology · 1

Development of non-hematological adverse events in apatinib-treated gastric cancer and their association with clinical outcome: Results from a phase IV study.

2018 · Yi Ba, Jin Li, et al. · Journal of Clinical Oncology · 1

Prognostic factors for survival in apatinib-treated gastric cancer: Results from a post-marketing phase IV study (Ahead-G201).

2018 · Shukui Qin, Wenying Deng, et al. · Journal of Clinical Oncology · 1

Clinical effectiveness of apatinib at different doses in patients with advanced gastric cancer as the third-line or further treatment: Results from a post-marketing phase IV study.

2021 · Jin Li, Shukui Qin, et al. · Journal of Clinical Oncology

BMI differences for clinical outcome in patients with advanced or metastatic gastric cancer treated with apatinib: Data from a post-marketing phase IV study (Ahead-G201).

2018 · Yu-Xian Bai, Shukui Qin, et al. · Journal of Clinical Oncology

Impact of time to progression on first-line therapy on clinical outcomes in advanced gastric cancer treated with apatinib: data from a phase IV study (Ahead-G201).

2018 · Zhong Xie, Shukui Qin, et al. · Journal of Clinical Oncology

Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.

2018 · Shukui Qin, Lu Wen, et al. · Journal of Clinical Oncology

Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201).

2018 · Yifu He, Jin Li, et al. · Journal of Clinical Oncology

Effect of ECOG PS on outcome of advanced or metastatic gastric patients treated with apatinib: Analysis from a post-marketing phase IV study.

2018 · Xiaoyan Lin, Jin Li, et al. · Journal of Clinical Oncology

Does hypertension history in patients with advanced gastric cancer has an impact on clinical outcomes following apatinib treatment? A subgroup analysis based on data from Ahead-G201 study.

2018 · Tienan Yi, Jin Li, et al. · Journal of Clinical Oncology

Association of proteinuria, hypertension, and hand-foot-skin reaction with efficacy of apatinib in gastric cancer: Results from the post-marketing study (Ahead-G201).

2018 · Jin Li, Wenying Deng, et al. · Journal of Clinical Oncology

Effect of region and hospital attribute on outcome of gastric patients treated with apatinib: Data from post-marketing phase IV study.

2018 · Haijun Zhong, Shukui Qin, et al. · Journal of Clinical Oncology

Effects of apatinib dose interruptions on safety and efficacy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction in third- or later-line setting.

2018 · Junsheng Wang, Shukui Qin, et al. · Journal of Clinical Oncology

Comparisons between intestinal and diffuse gastric cancer in response to apatinib: Data from post-marketing phase IV study.

2018 · Guifang Zhang, Shukui Qin, et al. · Journal of Clinical Oncology

Safety and efficacy of apatinib in elderly patients with advanced or metastatic gastric cancer in the post-marketing phase IV study: Subgroup analysis by age (Ahead-G201).

2018 · Lu Wen, Shukui Qin, et al. · Journal of Clinical Oncology

Apatinib as third-line or beyond therapy in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction: An open-label, multicenter, post-marketing phase IV study (Ahead-G201).

2018 · Shukui Qin, Wenying Deng, et al. · Journal of Clinical Oncology

Effects of gefitinib on cancer cell apoptosis and survival time of patients with advanced NSCLC

2017 · Tongfu Jia · 中国医师杂志

Quantitative detection of peripheral MDR genes in breast cancer before chemotherapy and their clinical significances

2008 · Xinmei Wang, Liang Li, et al. · The Chinese-German Journal of Clinical Oncology

Works count: 23

Citation count: 70

H-index: 4

I10-index: 2